Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Candida infections in children

Judith R Campbell, MD
Debra L Palazzi, MD, MEd
Section Editor
Sheldon L Kaplan, MD
Deputy Editor
Mary M Torchia, MD


The clinical manifestations of infection with Candida species range from local mucous membrane infection to widespread dissemination with multisystem organ failure. Candida are considered normal flora in the gastrointestinal and genitourinary tracts of humans but invade and cause disease when there is an imbalance in their ecologic niche. (See "Biology of Candida infections".)

This topic will provide an overview of Candida infections in children. Many of these infections are discussed in detail in other topic reviews; they are briefly summarized here. The clinical features, diagnosis, and treatment of candidemia in children and Candida infections in neonates are discussed separately.

(See "Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis".)

(See "Candidemia and invasive candidiasis in children: Management".)

(See "Epidemiology and risk factors for Candida infection in neonates".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Oct 25, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Lee GE, Kaufman DA, Zaoutis TE. Candidiasis. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 7th ed, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.2735.
  2. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.
  3. Su CW, Gaskie S, Jamieson B, Triezenberg D. Clinical inquiries. What is the best treatment for oral thrush in healthy infants? J Fam Pract 2008; 57:484.
  4. Horsfield P, Logan FA, Newey JA. Letter: Oral irritation with gentian violet. Br Med J 1976; 2:529.
  5. Leung AK. Gentian violet in the treatment of oral candidiasis. Pediatr Infect Dis J 1988; 7:304.
  6. John RW. Necrosis of oral mucosa after local application of crystal violet. Br Med J 1968; 1:157.
  7. Hoppe JE. Treatment of oropharyngeal candidiasis in immunocompetent infants: a randomized multicenter study of miconazole gel vs. nystatin suspension. The Antifungals Study Group. Pediatr Infect Dis J 1997; 16:288.
  8. Goins RA, Ascher D, Waecker N, et al. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. Pediatr Infect Dis J 2002; 21:1165.
  9. Boon JM, Lafeber HN, Mannetje AH, et al. Comparison of ketoconazole suspension and nystatin in the treatment of newborns and infants with oral candidosis. Mycoses 1989; 32:312.
  10. National Institute for Health and Care Excellence (NICE) Guidance: Postnatal care up to 8 weeks after birth (2006). Available at: https://www.nice.org.uk/guidance/CG37/chapter/1-Recommendations (Accessed on October 27, 2016).
  11. Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 2010; :CD003940.
  12. Flynn PM, Cunningham CK, Kerkering T, et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. J Pediatr 1995; 127:322.
  13. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death. http://www.fda.gov/Drugs/DrugSafety/ucm500597.htm (Accessed on June 01, 2016).
  14. Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: Retrospective review of boric acid therapy. Clin Infect Dis 1997; 24:649.
  15. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26:259.
  16. Kirkpatrick CH. Chronic mucocutaneous candidiasis. In: Candidiasis pathogenesis, diagnosis, and treatment, Bodey GP (Ed), Raven Press, New York 1993. p.167.
  17. Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections--treatment. Clin Infect Dis 2011; 52 Suppl 6:S457.
  18. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30:14.
  19. Calandra T, Bille J, Schneider R, et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2:1437.
  20. Cheng IK, Fang GX, Chan TM, et al. Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment. Q J Med 1989; 71:407.
  21. Ward RM, Sattler FR, Dalton AS Jr. Assessment of antifungal therapy in an 800-gram infant with candidal arthritis and osteomyelitis. Pediatrics 1983; 72:234.
  22. Swanson H, Hughes PA, Messer SA, et al. Candida albicans arthritis one year after successful treatment of fungemia in a healthy infant. J Pediatr 1996; 129:688.
  23. Harris MC, Pereira GR, Myers MD, et al. Candidal arthritis in infants previously treated for systemic candidiasis during the newborn period: report of three cases. Pediatr Emerg Care 2000; 16:249.
  24. Butler KM, Baker CJ. Candida: an increasingly important pathogen in the nursery. Pediatr Clin North Am 1988; 35:543.
  25. Murphy K, Bradley J, James HE. The treatment of Candida albicans shunt infections. Childs Nerv Syst 2000; 16:4.
  26. Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50.
  27. Mayayo E, Moralejo J, Camps J, Guarro J. Fungal endocarditis in premature infants: case report and review. Clin Infect Dis 1996; 22:366.
  28. Aspesberro F, Beghetti M, Oberhänsli I, Friedli B. Fungal endocarditis in critically ill children. Eur J Pediatr 1999; 158:275.
  29. Thaler M, Pastakia B, Shawker TH, et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108:88.